A Comparative Analysis of the C $\bar{1}$ -Binding Ability of Fragments Derived from Complement-Fixing and Noncomplement-Fixing IgM Proteins

MARY M. HURST, JOHN E. VOLANAKIS, ROBERT M. STROUD, and
J. CLAUDE BENNETT

*From the Division of Clinical Immunology and Rheumatology and the
Department of Microbiology, University of Alabama Medical Center,
Birmingham, Alabama 35294*

ABSTRACT The purpose of this study was to examine the molecular parameters necessary for initiation of complement fixation by IgM proteins. To determine why some IgM molecules are capable of complement fixation while others are not, several different Waldenström IgM proteins were examined for their ability to fix total hemolytic complement in the CH₅₀ assay. Subsequently, the C $\bar{1}$ fixing ability of a 56-residue fragment derived from the C μ 4 domain of each of these IgM molecules was studied with the C $\bar{1}$ fixation assay.

One of the three Waldenström IgM proteins (Gr) used in the present study was found unable to consume complement in a CH₅₀ assay when tested at the same concentration as the two complement-consuming IgM molecules (Dau and Bus). However, when the 56-residue C μ 4 fragment from the C μ 4 domain of each IgM molecule was tested for C $\bar{1}$ -fixing ability, all three were found to bind C $\bar{1}$.

On the basis of these observations, it is proposed that a C $\bar{1}$ binding site exists within the C μ 4 domain of both complement-fixing and noncomplement-fixing IgM molecules. Presumably, the latter molecules are unable to interact in their native state with C $\bar{1}$ in the manner required for initiation of the classical complement pathway, possibly due to the configurational inaccessibility of the entire C $\bar{1}$ binding site.

INTRODUCTION

There have been several reports in the literature suggesting the existence of two IgM subclasses, one capable of fixing complement and the second consisting of noncomplement-fixing IgM antibodies (1-4). In one

such study Onoue and Ikeda (3) reported the identification of three noncomplement-fixing Waldenström IgM proteins out of a group of six. In a more recent publication, Tanimoto, et al. (4) reported that whereas a group of three monoclonal IgM-rheumatoid factor molecules were found to lack complement-fixing activity in a direct hemolytic assay system, three polyclonal rheumatoid factors were found capable of fixing and activating complement via the classical pathway. These authors suggested that IgM-rheumatoid factor may be composed of a mixture of complement-fixing and noncomplement-fixing antibodies, the noncomplement-fixing IgM either lacking the C $\bar{1}$ binding site or possessing configurations that interfere with C $\bar{1}$ binding.

We reported previously that a 6,800 mol wt fragment, designated C μ 4 fragment, derived from the terminal C μ 4 domain of the complement-fixing Waldenström IgM, Dau, was capable of binding the activated first component of complement (C $\bar{1}$) (5). Due to mounting evidence that a considerable degree of homology in primary structure exists within the Fc region of all human pathological μ heavy chains (6), it seemed logical that the isolated C μ 4 fragment from either a complement-fixing or noncomplement-fixing IgM should be able to fix C $\bar{1}$. We therefore compared the C $\bar{1}$ fixing ability of the C μ 4 fragment isolated from the noncomplement-fixing IgM molecule, Gr, with that of the same fragment derived from the complement-fixing IgM molecules, Dau and Bus. The C μ 4 fragment from each of these three molecules was found to bind C $\bar{1}$, lending support to the hypothesis that noncomplement-fixing IgM proteins do indeed contain C $\bar{1}$ binding sites, these sites being either inaccessible to C $\bar{1}$ in the native state, or only partially accessible so that even though C $\bar{1}$ does attach, it is unable to interact with the other early complement components.

*Received for publication 26 November 1975 and in revised form
13 February 1976.*

METHODS

Preparation of IgM and its (Fc)₅μ and C_H4 fragments. Human Waldenström IgM from patients Dau, Bus, and Gr was obtained as described by Hester et al. (7). (Fc)₅μ and Fab_μ fragments were prepared by trypsin digestion (trypsin-TPCK, Worthington Biochemical Corp., Freehold, N. J.) at 60°C for 20 min (7, 8). After separation of (Fc)₅μ and Fab_μ on Sephadex G-200 (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) in 1% NH₄HCO₃, pH 8, the (Fc)₅μ was further purified on Bio-Gel A-15 (Bio-Rad Laboratories, Richmond, Calif.). (Fc)₅μ fragments were incubated with 0.05 M cysteine (Fisher Scientific Co., Pittsburgh, Pa.) for 8 min at 25°C in 0.05 M Tris (Sigma Chemical Co., St. Louis, Mo.) buffer (pH 8.6), containing 0.1 M sodium chloride to produce monomeric Fc_μ fragments. After alkylation with a 10% excess of iodoacetamide (Sigma Chemical Co.), homogeneous Fc_μ fragments were isolated by gel chromatography on Sephadex G-200 (7). Limited tryptic cleavage of Fc_μ to produce the C_H4 fragment was performed by the method of Hester et al. (7). Trypsin-TPCK was added at an enzyme-to-substrate ratio of 1:100 to a 5 mg/ml preparation of Fc_μ fragments in 0.05 M Tris buffer (pH 8.0) containing 0.1 M sodium chloride and 0.01 M CaCl₂. After incubation at 37°C for 16 min, digestion was terminated by the addition of an amount of soybean trypsin inhibitor (Worthington Biochemical Corp.) equivalent in weight to the quantity of trypsin used. Solid guanidine-HCl (Schwarz/Mann Div., Becton, Dickinson & Co., Orangeburg, N. Y.) was then added to a final concentration of 5 M and the sample applied to a Sephadex G-75 column. The C_H4 fragment was further purified by passage through a column of Bio-Gel P-10 in 5 M guanidine-HCl.

A detailed account of these methodologies and characterization of the fragments obtained from Gr IgM has been published by Hester et al. (7). The fragments isolated from Dau and Bus IgM molecules behaved identically to the Gr fragments during both fractionation and characterization.

After centrifugation for 1 h at 100,000 g, protein concentrations were determined spectrophotometrically at 280 nm with $E_{1\%}^{1\text{cm}}$ of 12.0 for IgM and for (Fc)₅μ. The C_H4 fragments were desalted in 1% NH₄HCO₃, lyophilized, and weighed directly. A measured aliquot of the parent stock solution of each C_H4 fragment was removed for quantitative amino acid analysis.

Amino acid analyses. Samples were hydrolyzed in constantly boiling HCl in vacuum-sealed tubes for 20 h. After evaporation, the samples were analyzed on a Durrum model D-200 automatic amino acid analyzer with high-speed analysis and the single-column technique (Durrum Instrument Corp., Palo Alto, Calif.).

Gel electrophoresis. Disc electrophoresis was performed with 5% polyacrylamide, as described by Maizel (9). The gels were run in 0.1 M sodium phosphate buffer (pH 7.2) containing 0.1% sodium dodecyl sulfate and 0.5 M urea, stained for 15–30 min with 1% amido black (Gallard-Schlesinger Chemical Mfg. Co., Carle Place, N. Y.) in 7% acetic acid, and destained in 40% absolute methanol and 10% acetic acid.

Buffers used in complement assays. Gelatin-veronal buffer is barbital-buffered saline (VBS)¹ containing 0.1% gelatin, 0.15 mM CaCl₂, and 1 mM MgCl₂, with a relative salt concentration of 0.15. The relative salt concentration of each buffer was monitored by relating the electrical resistance of the buffer at 0°C to a standard curve obtained by graphing the resistance of NaCl solutions vs. the NaCl molarities (10).

¹ Abbreviation used in this paper: VBS, veronal-buffered saline.

Dextrose-gelatin VBS⁺⁺ is VBS diluted with 5% dextrose to a relative salt concentration of 0.075, containing standard amounts of gelatin, Ca⁺⁺, and Mg⁺⁺ (11). Dextrose VBS⁺⁺, the buffer used for dilution of immunoglobulin and its fragments, refers to dextrose-gelatin VBS minus the gelatin. VBS containing 0.02 M EDTA and 0.1% gelatin (EDTA-gelatin-VBS) was also used as a buffer in the complement assays (11).

Complement components and intermediates. Partially purified human C₁ and guinea pig C₂ were prepared as described by Nelson et al. (12). EAC⁴_{hu} (sheep erythrocytes sensitized with rabbit antibody to E, to which complement components have been added) were made by a slight modification of the method described by Borsos and Rapp (13), using guinea pig (gp) C₁ (500 effective molecules/cell). EAC¹_{gp}⁴_{hu} were prepared by adding 500 effective molecules of C₁ per EAC₄ cell. As a source of the later-reacting complement components (C₃–9), guinea pig serum was used at a dilution of 1:40 in 20 mM EDTA buffer.

CH₅₀ fixation assay. Consumption of human hemolytic complement was demonstrated by quantitative assay of residual hemolytic activity in fresh normal human serum after incubation with immunoglobulin fragments, or with buffer as a control, for 1 h at 37°C. In this procedure 0.25-ml aliquots of fresh normal human serum were mixed with 1.125 ml of immunoglobulin fragment dissolved in gelatin VBS⁺⁺. After incubation for 1 h at 37°C, the residual hemolytic complement activity was measured as described by Mayer (11).

C₁ binding assay. The C₁ fixing ability of the IgM molecules and their respective fragments was examined with a modified C₁ fixation assay (5). The buffer utilized throughout the assay was dextrose-gelatin VBS⁺⁺ of relative salt concentration 0.065, containing optimum amounts of Ca⁺⁺ and Mg⁺⁺ (10). An amount of functionally pure human C₁ (14) sufficient to yield 63% lysis was incubated with serial dilutions of the test fragments or with buffer as a control for 10 min at 30°C. EAC₄ (1.5 × 10⁸/ml) were then added and incubation was allowed to proceed for an additional 10 min. The resulting EAC₁₄ cells were washed twice to remove unbound C₁ and resuspended in the same buffer. An excess of functionally pure C₂ (12) was then added, followed by an excess of C₃–9, and the degree of lysis was determined spectrophotometrically at 412 nm.

The controls used for this assay consisted of the following: (a) a cell blank (cells plus buffer), (b) a complete lysis control (cells plus water to obtain 100% lysis), (c) a cell blank plus complement (buffer substituted for test serum dilutions to insure that no extraneous C₁ was in any of the reagents), and (d) a complement color (buffer plus guinea pig serum-EDTA) (10).

RESULTS

After passage of the 60°C tryptic digests of each IgM protein through a Sephadex G-200 column, and subsequent purification of the (Fc)₅μ fragments on Bio-Gel A-15, an (Fc)₅μ fraction was obtained that gave a single immunoelectrophoretic band with anti-IgM, and did not react with anti-Bence Jones κ or anti-Bence Jones λ antisera (Meloy Laboratories Inc., Springfield, Va.). Dau (Fc)₅μ has been characterized by Zikán and Bennett (15), and Hester et al. (7) have published a detailed analysis of Gr (Fc)₅μ.

Pentameric Fc was reduced with 50 mM cysteine and the 34,000-mol wt monomer isolated on a Sephadex

G-200 column in pH 7.5 phosphate buffer (7). Disc electrophoresis in 5% polyacrylamide with a pH 7.2 sodium phosphate-0.1% sodium dodecyl sulfate-50 mM urea buffer revealed a single band whose molecular weight was not lowered after reduction and alkylation in 5 M guanidine-HCl (7). Furthermore, Hester et al. (7) found that total reduction of Gr monomeric Fc μ released four SH groups per fragment, indicating that the two intrachain disulfide loops had remained intact.

The Fc μ fragment was treated with trypsin for 16 min at 37°C and the digest passed through a Sephadex G-75 column in 5 M guanidine-HCl (7). The peak containing the C μ 4 fragments was pooled, desalted on Sephadex G-25 in 1% NH₄HCO₃, lyophilized, and applied to a Bio-Gel P-10 column in 5 M guanidine-HCl. After elution from the P-10 column, the C μ 4 fragments from each of the IgM proteins gave a single band on 5% sodium dodecyl sulfate acrylamide gels. The gel filtration patterns and fragment analyses obtained during the fragmentation of Gr IgM have been published by Hester et al. (7). Similar patterns and products resulted from the fragmentation of Dau and Bus IgM molecules. Partial sequence analysis and a comparison of the amino acid composition of the Gr C μ 4 fragment and of its respective isolated peptide chains with that published for the IgM,

TABLE I
Amino Acid Composition of the C μ 4 Fragment from Dau and Bus IgM

	Dau C μ 4 Fragment*	Bus C μ 4 Fragment*	Theor.†
His	1.9	1.8	2
Arg	2.3	2.2	2
S-CMC	ND§	ND	
Asp	3.0	3.0	3
Thr	6.3	6.2	7
Ser	3.7	3.5	4
Glu	7.9	7.7	8
Pro	2.0	2.0	2
Gly	2.0	2.0	2
Ala	4.7	4.7	5
Val	5.7	5.6	6
Met	1.2	1.1	1
Ile	2.0	2.0	2
Leu	3.0	3.0	3
Tyr	1.7	1.7	2
Phe	2.7	2.8	3
Trp	ND	ND	2
Lys	0	0	0

* Residues per three residues of leucine.

† Residues 468-491 and 515-546 of the IgM, Ou, from Florent et al. (6).

§ ND, not determined.

TABLE II
Consumption of Human Complement by Dau IgM C μ 4 and (Fc) $\delta\mu$ Fragments

Test sample	Total complement	
	CH ₅₀	Molar ratio*
	nmol ⁻¹	
C μ 4	2.2	1.0
(Fc) $\delta\mu$	17.0	7.7
IgM	23.0	10.4

* For each series of titrations the molar ratios refer back to the C μ 4 fragment as 1.

Ou (6), enabled Hester et al. (7) to pinpoint its location within the μ chain. The C μ 4 fragment was found to be composed of the C μ 4 domain of the Fc μ minus two tryptic peptides in the center of the loop (residues 468-491 disulfide bonded to residues 515-546, according to the residue numbering of Ou[6]). Amino acid compositional analysis of the Dau and Bus C μ 4 fragments (Table I) and a spot check via double sequencing in our automated sequencer of the intact Dau C μ 4 fragment (16) revealed no differences as compared to the Gr C μ 4 fragment (7).

Initially, the CH₅₀ assay was used to test the overall complement-consuming ability of the Waldenström IgM, Dau, and its (Fc) $\delta\mu$ and C μ 4 fragments. As seen in Table II, the Dau C μ 4 fragment consumed 2.2 CH₅₀ U/nmol, while the Dau (Fc) $\delta\mu$ consumed 17 CH₅₀ U/nmol. (Fc) $\delta\mu$ was therefore 7.7 times more efficient than the C μ 4 fragment at consuming total complement. Furthermore, on a molar basis, intact Dau IgM appeared to be approximately 10 times more efficient in consuming total complement than the monomeric C μ 4 fragment. This latter observation provides an impressive quantitative correlation, since there are 10 C μ 4 fragments per IgM molecule.

Subsequently, the ability of two other Waldenström IgM proteins (Bus and Gr) to fix total complement was examined with the CH₅₀ assay. As depicted in Table III, Bus IgM was found to consume total complement, whereas an equivalent amount of Gr IgM did not.

For the final set of experiments, the C μ 4 fragment was isolated from Dau, Bus, and Gr IgM proteins and tested in the C $\bar{I}$ fixation assay (Table III). It was found that the C μ 4 fragment from each of these IgM molecules was able to fix C $\bar{I}$, with 8 μ g of Dau and Bus C μ 4 fragments and 24 μ g of Gr C μ 4 fragment required to fix one-half of the available C $\bar{I}$. Fig. 1 is a graph of these results. It should be noted that although the Gr C μ 4 fragment appears to be slightly less efficient than the Dau and Bus C μ 4 fragments in binding C $\bar{I}$, the molar ratios for the three fragments are of the same order of magnitude.

TABLE III
Complement-Binding Properties of Three Different Waldenström IgM Molecules and of Their Respective C_H4 Fragments

Source of IgM	Total C' fixation by IgM		C _I fixation by C _H 4 fragments	
	CH ₅₀	Molar ratio*	Amount†	Molar ratio‡
	nmol ⁻¹		μg	
Dau	23.0	1.0	8	1
Bus	4.8	4.8	8	1
Gr	0	>100	24	3

* For these titrations the molar ratios refer back to Dau IgM as 1.

† Amount required to bind 50% of the available C_I.

‡ For this titration the molar ratios refer back to the Dau C_H4 fragment as 1.

DISCUSSION

It has been suggested by Edelman et al. (17) that certain repeating regions of immunoglobulin polypeptide chains are folded into compact globular structures called domains, each evolved to perform a particular biologic function. According to this concept, it should be possible to associate specific biological effector functions, such as complement fixation, with a specific submolecular domain in certain immunoglobulin molecules. Evidence to support this hypothesis has been obtained from the data of Connell and Porter (18) and of Ellerson et al. (19) demonstrating that the C_γ2 domain of IgG contains a C_I binding site (Fig. 2) and

FIGURE 1 Fixation of human C_I by the C_H4 fragments isolated from three different Waldenström IgM proteins, Dau, Bus, and Gr. Enough C_I to produce 63% lysis of the cells in absence of test material was used. After incubation, the amount of unbound C_I was determined and expressed as a percentage of that found when no test material was added during the incubation.

FIGURE 2 Diagrammatic representation of an IgG 1 myeloma protein and of one of the five subunits of a Waldenström IgM protein. The four homology regions of the IgG heavy chain (V_H and C_γ1-C_γ3) and the five homology regions of the IgM heavy chain (V_H and C_μ1-C_μ4) are marked. The locations of disulfide bonds, carbohydrate groups, and amino acid residues were taken from Edelman et al. (17) for IgG and from Florent et al. (6) for IgM. The sequences found to be capable of C_I fixation are indicated with broad lines.

may therefore play a role in complement activation by this molecule.

Few attempts have been made to delineate the structural basis for complement binding to IgM. However, two meaningful observations relative to this question have been published. First, the 7S subunit of IgM was found to bind C_I as effectively as nonaggregated, monomeric IgG in a C_I fixation test (20), and second, the (Fc)_δμ and Fcμ fragments of IgM were found to have similar complement-fixing capacities in a CH₅₀ assay, each being 31 times as effective as intact IgM by weight and 19 times as effective on a molar basis (21).

In a more recent study from this laboratory (5), it was reported that a 56-residue fragment (designated C_H4 fragment), derived from a Waldenström IgM protein and consisting of 24 residues of the amino-terminal portion of the C_μ4 domain disulfide bonded to 32 residues of the carboxy-terminal region of the loop, possessed C₁ fixing ability in a C₁ fixation assay. On the basis of these data, and the observation that upon incubation with normal human serum the C_H4 fragment consumes C4 (16), it is proposed that a classical complement fixation function, i.e., C1 binding and activation, can be localized within the C_μ4 domain of the IgM molecule (Fig. 2).

The sequence data presented by Florent et al. (6) indicate that only minor differences exist in the primary structure of the Fc region of both pathological and normal IgM molecules. This being true, it follows that if primary structure relates directly to function, the C_H4 fragment from complement-fixing and from noncomplement-fixing molecules should possess C₁ fixing ability. Whether or not each respective IgM could fix C₁ so that it could subsequently interact with the other early complement components would therefore depend upon the relative exposure of the C_μ4 domain in the intact molecule. This was indeed borne out by the fact that the isolated C_H4 fragment from the noncomplement-fixing IgM, Gr, was able to fix C₁, and did so nearly as efficiently as the C_H4 fragments from the complement-fixing IgM molecules, Dau and Bus. The threefold difference in C₁-fixing ability observed between the C_H4 fragments from complement-fixing and noncomplement-fixing molecules was not felt to be significant.

That the C_H4 fragments from two complement-fixing IgM molecules (Dau and Bus) and from an apparent noncomplement-fixing IgM protein (Gr) were each capable of C₁ fixation raises interesting possibilities. In this regard it should be pointed out that Isenman et al. (22) found that while noncomplement-fixing IgG4 does not bind C₁, Fc fragments derived from this subclass do fix C₁, and do so with an affinity comparable to the corresponding fragment from IgG1. In an earlier publication these authors reported that the C₁ fixing site of β₂-microglobulin remains active after reduction and alkylation (23). Furthermore, they obtained spectral data indicating that in the absence of an intact intrachain disulfide bond, β₂-microglobulin does not fold into the conformation characteristic of the native state. On the basis of these data Isenman and co-workers postulated that little secondary or tertiary folding is required for the existence of an active C1 binding site, and that the chemical features of the linear amino acid sequence required for binding of C₁ may be commonplace but may be prevented from re-

acting because of local folding patterns or interaction with one-dimensionally distant regions of the molecule (22). Such an interpretation is consistent with our observation that fragments derived from the C_μ4 domain of both complement-fixing and noncomplement-fixing IgM molecules retain the ability to fix C₁.

Considering our data on IgM relative to that of Isenman and colleagues on IgG4 and β₂-microglobulin, we suggest that a C₁ fixing site may exist in all IgG and IgM proteins, the noncomplement-fixing molecules possessing configurations that interfere with correct C₁ binding.

ACKNOWLEDGMENTS

This work was supported in part by grants AI 9153, HL 11310, PPG AM 03555, and NSF BMS 74-11522 from the National Institutes of Health, and credit is given to project 8197-01, Veterans Administration Hospital, Birmingham, Ala.

REFERENCES

- Colombani, J., M. Colombani, and J. Dausset. 1973. Noncomplement-fixing IgM antibodies with anti-HL-A2 specificity and blocking activity. *Transplantation (Baltimore)*. 16: 257-260.
- MacKenzie, M. R., N. Creevy, and M. Heh. 1971. The interaction of human IgM and C1q. *J. Immunol.* 106: 65-68.
- Onoue, K., and M. Ikeda. 1975. Polymorphism of complement fixing activity of IgM. *Jpn. J. Allergy*. 24: 50-79.
- Tanimoto, K., N. R. Cooper, J. S. Johnson, and J. H. Vaughan. 1975. Complement fixation by rheumatoid factor. *J. Clin. Invest.* 55: 437-445.
- Hurst, M. M., J. E. Volanakis, R. B. Hester, R. M. Stroud, and J. C. Bennett. 1974. The structural basis for binding of complement by immunoglobulin M. *J. Exp. Med.* 140: 1117-1121.
- Florent, G., D. Lehman, D. Lockhart, and F. W. Putnam. 1974. Identity of the Fc Fragments of pathological and normal immunoglobulin M. *Biochemistry*. 13: 3372-3381.
- Hester, R. B., J. E. Mole, and R. E. Schrohenloher. 1975. Evidence for the absence of noncovalent bonds in the Fc_μ region of IgM. *J. Immunol.* 114: 486-491.
- Plaut, A. G., and T. B. Tomasi, Jr. 1970. Immunoglobulin M: pentameric Fc_μ fragments released by trypsin at higher temperatures. *Proc. Natl. Acad. Sci. U. S. A.* 65: 318-322.
- Maizel, J. V., Jr. 1966. Acrylamide-gel electrophorograms by mechanical fractionation: radioactive adenovirus proteins. *Science (Wash. D. C.)*. 151: 988-990.
- Stroud, R. M., H. S. Shin, and E. Shelton. 1973. Complement components: assays, purification and ultrastructure methods. In *Methods in Molecular Biology, Immune Response at the Cellular Level Vol. VI*. Theodore P. Zacharia, editor. Marcel Dekker, Inc., New York. 161-211.
- Mayer, M. M. 1961. Complement and complement fixation. In *Experimental Immunochimistry*. E. A. Kabat and M. M. Mayer, editors. Charles C. Thomas, Publisher, Springfield, Ill. 2nd edition. 133-240.
- Nelson, R. A., Jr., J. Jensen, I. Gigli, and N. Tamura. 1966. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. *Immunochemistry*. 3: 111-135.

13. Borsos, T., and H. J. Rapp. 1967. Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement. *J. Immunol.* **99**: 263-268.
14. Tamura, N., and R. A. Nelson, Jr. 1968. The purification and reactivity of the first component of complement from guinea pig, human and canine sera. *J. Immunol.* **101**: 1333-1345.
15. Zikán, J. and J. C. Bennett. 1973. Isolation of F(c)_{sμ} and Fab_μ fragments of human IgM. *Eur. J. Immunol.* **3**: 415-419.
16. Hurst, M. M., J. E. Volanakis, R. M. Stroud, and J. C. Bennett. 1975. C1 fixation and classical complement pathway activation by a fragment of the Cμ4 domain of IgM. *J. Exp. Med.* **142**: 1322-1326.
17. Edelman, G. M., B. A. Cunningham, W. E. Gall, P. D. Gottlieb, U. Rutishauser, and M. J. Waxdal. 1969. The covalent structure of an entire γG immunoglobulin molecule. *Proc. Natl. Acad. Sci. U. S. A.* **63**: 78-85.
18. Connell, G. E., and R. R. Porter. 1971. A new enzymic fragment (Fab_c) of rabbit immunoglobulin G. *Biochem. J.* **124**: 53P. (Abstr.)
19. Ellerson, J. R., D. Yasmeen, R. H. Painter, and K. J. Dorrington. 1972. A fragment corresponding to the C_H2 region of immunoglobulin G (IgG) with complement fixing activity. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* **24**: 318-322.
20. Augener, W., H. M. Grey, N. R. Cooper, and H. J. Müller-Eberhard. 1971. The reaction of monomeric and aggregated immunoglobulins with C1. *Immunochemistry.* **8**: 1011-1030.
21. Plaut, A. G., S. Cohen, and T. B. Tomasi, Jr. 1972. Immunoglobulin M: fixation of human complement by the Fc fragment. *Science (Wash. D. C.)*. **176**: 55-56.
22. Isenman, D. E., K. J. Dorrington, and R. H. Painter. 1975. The structure and function of immunoglobulin domains. II. The importance of interchain disulfide bonds and the possible role of molecular flexibility in the interaction between immunoglobulin G and complement. *J. Immunol.* **114**: 1726-1729.
23. Isenman, D. E., R. H. Painter, and K. J. Dorrington. 1975. The structure and function of immunoglobulin domains: studies with Beta₂-microglobulin on the role of the intrachain disulfide bond. *Proc. Nat. Acad. Sci. U. S. A.* **72**: 548-552.